Stock comparison
Eli Lilly
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 62C | LLY |
| Benjamin Graham | 86A | 69B | LLY |
| Philip Fisher | 86A | 53C | LLY |
| Peter Lynch | 74B | 35D | LLY |
| Joel Greenblatt | 78C | 46D | LLY |
| Charlie Munger | 85A | 69C | LLY |
| Terry Smith | 77C | 66B | LLY |
Side-by-side metrics
| Metric | LLY | NVS |
|---|---|---|
| Market cap | $1T | $290.64B |
| P/E (TTM) | 36.6x | 21.3x |
| EV/EBIT | 34.1x | 19.2x |
| ROIC (TTM) | 32.06% | 14.89% |
| Gross margin | 83.51% | 75.13% |
| Net margin | 34.98% | 24.31% |
| Revenue CAGR 5y | 23.17% | 5.66% |
| EPS CAGR 5y | 40.81% | -9.29% |
| Debt / Equity | 1.4x | 1.2x |
| Dividend yield | 0.62% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- EPS CAGR 5y40.81%vs -9.29%+123%
- Revenue CAGR 5y23.17%vs 5.66%+76%
- Market cap$1Tvs $290.64B+71%
- ROIC (TTM)32.06%vs 14.89%+54%
NVS leads on
- Dividend yield3.12%vs 0.62%+80%
- EV/EBIT19.2xvs 34.1x+44%
- P/E (TTM)21.3xvs 36.6x+42%
- Debt / Equity1.2xvs 1.4x+12%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.